Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61% and 76%, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN.

Original languageEnglish (US)
Pages (from-to)1039-1043
Number of pages5
JournalBlood
Volume111
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Leukemia, Myeloid, Chronic Phase
Treatment Failure
Interferons
Cytogenetics
Safety
Survival
Therapeutics
Imatinib Mesylate
Standard of Care
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases

ASJC Scopus subject areas

  • Hematology

Cite this

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. / Hochhaus, Andreas; Druker, Brian; Sawyers, Charles; Guilhot, Francois; Schiffer, Charles A.; Cortes, Jorge; Niederwieser, Dietger W.; Gambacorti, Carlo; Stone, Richard M.; Goldman, John; Fischer, Thomas; O'Brien, Stephen G.; Reiffers, Jose J.; Mone, Manisha; Krahnke, Tillmann; Talpaz, Moshe; Kantarjian, Hagop M.

In: Blood, Vol. 111, No. 3, 2008, p. 1039-1043.

Research output: Contribution to journalArticle

Hochhaus, A, Druker, B, Sawyers, C, Guilhot, F, Schiffer, CA, Cortes, J, Niederwieser, DW, Gambacorti, C, Stone, RM, Goldman, J, Fischer, T, O'Brien, SG, Reiffers, JJ, Mone, M, Krahnke, T, Talpaz, M & Kantarjian, HM 2008, 'Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment', Blood, vol. 111, no. 3, pp. 1039-1043. https://doi.org/10.1182/blood-2007-07-103523
Hochhaus, Andreas ; Druker, Brian ; Sawyers, Charles ; Guilhot, Francois ; Schiffer, Charles A. ; Cortes, Jorge ; Niederwieser, Dietger W. ; Gambacorti, Carlo ; Stone, Richard M. ; Goldman, John ; Fischer, Thomas ; O'Brien, Stephen G. ; Reiffers, Jose J. ; Mone, Manisha ; Krahnke, Tillmann ; Talpaz, Moshe ; Kantarjian, Hagop M. / Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. In: Blood. 2008 ; Vol. 111, No. 3. pp. 1039-1043.
@article{92943a23107a4327a534709507c92e78,
title = "Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment",
abstract = "Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67{\%} and 57{\%}, respectively. At the 5-year landmark, 184 (41{\%}) of the 454 patients are in CCyR. At more than 6 years, 199 (44{\%}) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61{\%} and 76{\%}, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN.",
author = "Andreas Hochhaus and Brian Druker and Charles Sawyers and Francois Guilhot and Schiffer, {Charles A.} and Jorge Cortes and Niederwieser, {Dietger W.} and Carlo Gambacorti and Stone, {Richard M.} and John Goldman and Thomas Fischer and O'Brien, {Stephen G.} and Reiffers, {Jose J.} and Manisha Mone and Tillmann Krahnke and Moshe Talpaz and Kantarjian, {Hagop M.}",
year = "2008",
doi = "10.1182/blood-2007-07-103523",
language = "English (US)",
volume = "111",
pages = "1039--1043",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

AU - Hochhaus, Andreas

AU - Druker, Brian

AU - Sawyers, Charles

AU - Guilhot, Francois

AU - Schiffer, Charles A.

AU - Cortes, Jorge

AU - Niederwieser, Dietger W.

AU - Gambacorti, Carlo

AU - Stone, Richard M.

AU - Goldman, John

AU - Fischer, Thomas

AU - O'Brien, Stephen G.

AU - Reiffers, Jose J.

AU - Mone, Manisha

AU - Krahnke, Tillmann

AU - Talpaz, Moshe

AU - Kantarjian, Hagop M.

PY - 2008

Y1 - 2008

N2 - Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61% and 76%, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN.

AB - Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61% and 76%, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN.

UR - http://www.scopus.com/inward/record.url?scp=38949178846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949178846&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-07-103523

DO - 10.1182/blood-2007-07-103523

M3 - Article

VL - 111

SP - 1039

EP - 1043

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -